Oncternal Therapeutics, Inc. Common Stock

ONCT US68236P1075 inactive

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

🔗
Website
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
5
🙍
Insiders
2
Person Price Shares Total Published Completed
Wills Robert James
 8.96
USD 		3,086
Bought 		27,655
USD 		08/04/2024 08/04/2024
Wills Robert James
 8.48
USD 		6,914
Bought 		58,602
USD 		28/03/2024 28/03/2024
Hale David F
 9.04
USD 		266
Bought 		2,405
USD 		23/02/2024 23/02/2024
Wills Robert James
 9.04
USD 		980
Sold 		8,859
USD 		23/02/2024 23/02/2024
Hale David F
 9.04
USD 		714
Bought 		6,455
USD 		23/02/2024 23/02/2024
Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Oncternal Therapeutics, Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Last 52W Low 52W High All-Time Low All-Time High β
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Wills Robert James 3 95,116.14 31,705.38 23/02/2024 08/04/2024
Hale David F 2 8,859.20 4,429.60 23/02/2024 23/02/2024

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.